Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + levamlodipine
- Development stage
- Phase 3
- Lead developer
- AHN-GOOK PHARMACEUTICAL
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valsartan + levamlodipine is a fixed-dose combination drug formulated to treat **high blood pressure (hypertension)**. It consists of **valsartan**, an angiotensin II receptor antagonist (ARB), and **levamlodipine**, the active enantiomer of amlodipine, a dihydropyridine-type calcium channel blocker. - **Valsartan** works by selectively blocking the angiotensin II type 1 receptor, preventing vasoconstriction and lowering blood pressure. - **Levamlodipine** blocks L-type calcium channels in vascular smooth muscle, resulting in vasodilation and reduced systemic vascular resistance. This combination enables synergistic blood pressure reduction via complementary mechanisms: ARB-induced vasodilation and dihydropyridine CCB-mediated calcium channel blockade. The combination is typically offered as an oral tablet for the management of patients whose hypertension is not adequately controlled with monotherapy.
- Other names
- valsartan + levamlodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)
Beyond the preview
Go deeper on valsartan + levamlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + levamlodipine.